Literature DB >> 20219351

Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands.

A E Dassen1, V E P P Lemmens, L V van de Poll-Franse, G J Creemers, S J Brenninkmeijer, D J Lips, A A M Vd Wurff, K Bosscha, J W W Coebergh.   

Abstract

BACKGROUND: Survival of gastric cancer in the Western world remains poor. We conducted a retrospective population-based study to evaluate trends in incidence, treatment and outcome of gastric adenocarcinoma.
METHODS: All patients diagnosed with gastric adenocarcinoma during 1990-2007 in the Dutch Eindhoven Cancer Registry area were included (n=4,797). Trend analyses were conducted for incidence, mortality, tumour and patient characteristics, treatment and crude overall survival, according to tumour location (cardia versus non-cardia). Temporal changes in the odds of undergoing surgery and the risk of death were analysed by means of multivariable regression methods.
RESULTS: Age-standardised incidence decreased among males (24-12 per 100,000 inhabitants) and females (10-6); mortality rates decreased at a similar pace. The proportion of cardia tumours remained stable. Stage distribution worsened over time among patients with cardia (stages I and II: 32% in 1990-1993 and 22% in 2006-2007, p=0.005) and non-cardia (stage IV: 33% in 1990-1993 and 40% in 2006-2007, p=0.0003) cancer. Chemotherapy rates increased in all settings. Five-year survival worsened over time for patients with non-cardia tumours. Age and stage had significant influence on survival after stratification for tumour localisation. After adjustments for relevant factors (i.e. stage), the risk of death decreased since the late 90s for patients with a cardia tumour (hazard ratio 0.8, p=0.01).
CONCLUSION: The absence of improvement in survival rates indicates the need for earlier detection and prospective studies to evaluate new therapy regimens with standardised surgery and pathology. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20219351     DOI: 10.1016/j.ejca.2010.02.013

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  52 in total

1.  MicroRNA-6852 suppresses cell proliferation and invasion via targeting forkhead box J1 in gastric cancer.

Authors:  Hui Yu; Jing Zhang; Qu Wen; Yi Dai; Wanli Zhang; Fen Li; Juan Li
Journal:  Exp Ther Med       Date:  2018-08-02       Impact factor: 2.447

Review 2.  Multimodal treatment of gastric cancer in the west: Where are we going?

Authors:  Daniele Marrelli; Karol Polom; Giovanni de Manzoni; Paolo Morgagni; Gian Luca Baiocchi; Franco Roviello
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

3.  Modest overall survival improvements from 1998 to 2009 in metastatic gastric cancer patients: a population-based SEER analysis.

Authors:  Sabrina M Ebinger; René Warschkow; Ignazio Tarantino; Bruno M Schmied; Ulrich Güller; Marc Schiesser
Journal:  Gastric Cancer       Date:  2015-09-21       Impact factor: 7.370

4.  The downregulation of miR-519a predicts poor prognosis and contributes to tumor progression in gastric cancer.

Authors:  Huimei Cai; Hui Lin; Wenyu Cao; Juan Sun; Yudian Huang; Yuehua Fang
Journal:  Int J Clin Exp Pathol       Date:  2019-07-01

5.  β-elemene enhances the radiosensitivity of gastric cancer cells by inhibiting Pak1 activation.

Authors:  Jun-Song Liu; Xiang-Ming Che; Shuai Chang; Guang-Lin Qiu; Shi-Cai He; Lin Fan; Wei Zhao; Zheng-Liang Zhang; Shu-Feng Wang
Journal:  World J Gastroenterol       Date:  2015-09-14       Impact factor: 5.742

Review 6.  Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review.

Authors:  Floortje Mols; Tonneke Beijers; Gerard Vreugdenhil; Lonneke van de Poll-Franse
Journal:  Support Care Cancer       Date:  2014-05-01       Impact factor: 3.603

7.  Trends in the management of gastric cancer over a 32-year period: a French population-based study.

Authors:  Elodie Herbreteau; Valérie Jooste; Samia Hamza; Côme Lepage; Jean Faivre; Anne-Marie Bouvier
Journal:  Gastric Cancer       Date:  2014-02-01       Impact factor: 7.370

8.  Clinical epidemiology of gastric cancer in Hehuang valley of China: a 10-year epidemiological study of gastric cancer.

Authors:  Su Yan; Bin Li; Zhen-Zhong Bai; Jun-Qi Wu; Da-Wei Xie; Ying-Cai Ma; Xu-Xiang Ma; Jun-Hui Zhao; Xin-Jian Guo
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

9.  Long-term quality-of-life comparison of total gastrectomy and proximal gastrectomy by postgastrectomy syndrome assessment scale (PGSAS-45): a nationwide multi-institutional study.

Authors:  Nobuhiro Takiguchi; Masazumi Takahashi; Masami Ikeda; Satoshi Inagawa; Shugo Ueda; Takayuki Nobuoka; Manabu Ota; Yoshiaki Iwasaki; Nobuyuki Uchida; Yasuhiro Kodera; Koji Nakada
Journal:  Gastric Cancer       Date:  2014-05-07       Impact factor: 7.370

10.  Evaluation of the Role of Circulating Long Non-Coding RNA H19 as a Promising Novel Biomarker in Plasma of Patients with Gastric Cancer.

Authors:  Doaa Hashad; Amany Elbanna; Abeer Ibrahim; Gihan Khedr
Journal:  J Clin Lab Anal       Date:  2016-05-17       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.